What you need to know
- 4.13Historic to contemporary drug testing: Withering’s digitalis soup, double-blindA trial in which neither the patients nor the researchers know who receives the drug and who receives the placebo. trials, placeboA dummy treatment that looks like the real drug but has no active ingredient, used as a comparison in trials. and three-phase testing.
This is an account of testing protocols, not prescribing advice. Digitalis/digoxin remains a potent, potentially toxic medicine. Phase descriptions follow NIH/NHLBI teaching summaries; exact modern regulatory codes vary by country and are not required recall.
By the end, you should be able to…
- Describe what Withering did, and the limits of that evidence.
- Explain placebo and double-blind design.
- Outline three phases of contemporary drug testing and why they are sequential.
Build your understanding
Digitalis soup: careful records, not a modern trial
In 1785 William Withering published An Account of the Foxglove. He identified Digitalis purpurea as the active plant in a herbal mixture used for dropsy (fluid accumulation, often linked to heart failure), recorded many cases, varied preparations and doses, and warned that the plant was poisonous if misused. That combination of botanical identification, dose-finding and written outcomes was unusually systematic for its time.
It was not a randomised, blinded, placebo-controlled trial. Patients were not allocated by chance, there was no matched inactive control, and Withering knew what he had given. Recovery could have involved rest, diet, other herbs or natural fluctuation. The lesson is the move from folklore towards recorded testing, not a claim that 163 case notes equal modern phase IIIThe third stage of clinical trials: large numbers of patients, comparing the drug with a placebo or an existing treatment. evidence.
Placebo and double-blind
A placeboA dummy treatment that looks like the real drug but has no active ingredient, used as a comparison in trials. is an inactive preparation that matches the look of the treatment. It controls for expectation, extra attention and the natural course of illness. If both groups improve equally, the chemical effect is not demonstrated.
In a double-blindA trial in which neither the patients nor the researchers know who receives the drug and who receives the placebo. study, neither the participant nor the clinician assessing them knows who received treatment or placebo. That reduces biased reporting and biased care. Single-blind hides the allocation from the participant only. Emergency unblinding must still be possible if safety requires it. Random allocation aims to balance unknown differences between groups.
Three phases, three questions
phase IThe first stage of clinical trials: a small group, often tens of people, mainly to test safety, side effects and dose. uses a small group, often tens of people, mainly for safety, side effects and early dose-finding. phase IIThe second stage of clinical trials: a larger group of patients, to look for evidence that the drug works and refine the dose. uses a larger group to look for effectiveness and to continue safety monitoring. Phase III uses a much larger group to confirm effectiveness, compare with standard treatment or placebo, and monitor less common side effects.
Phases are sequential because you should not expose thousands of people before basic safety and a signal of benefit exist. Passing a phase is not a guarantee of a licence, and later safety monitoring still occurs after approval. “Three-phase testing” in 4.13 is this sequence, not a promise of zero risk.
| Feature | Withering’s foxglove account | Contemporary trial |
|---|---|---|
| Control | No matched placebo group | Placebo or standard-treatment control |
| Allocation | Physician-chosen cases | Randomisation |
| Blinding | Physician and patient knew the plant was used | Often double-blind |
| Question | Does this preparation seem to help dropsy, and at what dose? | Safety, then efficacy, then comparison at scale |
Make your reasoning visible
Do not modernise Withering
Praise the records and dose caution without calling the book a double-blindA trial in which neither the patients nor the researchers know who receives the drug and who receives the placebo. trial.
Keep the phases distinct
I safety/dose, II effectiveness signal, III large comparison. Do not shuffle them.
Avoid this misconception
The claim: A double-blind trial means nobody involved in the hospital knows a trial is happening.
The correction: Participants consent to a trial. Double-blind means treatment identity is hidden from participant and assessor, not that the study itself is secret.
Order the stages of drug testing
Modern drug testing runs in a fixed order so that fewer people are exposed while least is known. Order the stages.
Order the steps
What to do
- Reorder the cards below: drag a card (on a touch screen, drag its number), tap a card then tap where it goes, or use the ↑ and ↓ arrows at its right.
- Press Check under the cards to mark each one green (right place) or red; the count shows how many are right.
- Stuck? Hint first outlines the first wrong place, then gives a clue, then places that step for you.
- Shuffle mixes the cards again; Start again returns them to the starting order. Keyboard: Space picks up, arrow keys move, Space drops.
Put the stages of modern drug testing in order.
1 of 6 in the right place
Withering tested digitalis on patients without these stages; that historic contrast is part of 4.13. Placebos are not used when an effective treatment already exists.
Check your understanding
Try each question before opening the suggested answer.
Practice question
Retrieval and explanation · suggested answer
Give two strengths and two limitations of Withering’s digitalis work as evidence.
Show suggested answer
Strengths: he identified the plant, recorded many cases, and adjusted dose while warning about toxicity. Limitations: no placebo control, no random allocation, and he knew who received digitalis, so bias and confounding remain.
Practice question
Retrieval and explanation · suggested answer
Why use a placebo in a double-blind pain trial?
Show suggested answer
Expectation can change reported pain. If neither participant nor assessor knows the allocation, differences are less likely to be caused by that expectation or by biased measurement.
Practice question
Retrieval and explanation · suggested answer
Why should Phase III not be the first test of a new plant-derived drug?
Show suggested answer
Large numbers should not be exposed before Phase I safety and Phase II evidence of possible benefit exist. Toxicity or lack of effect should be found on a smaller scale first.
Take the idea further
Apply the same specification knowledge to an unfamiliar problem. Any extra assumptions are supplied in the question.
Stretch question
A company tweets that its foxglove tablet “passed three-phase testing like Withering intended”. Identify two historical errors and one scientific caution.
Show a hint
Separate 1785 methods from modern phases.
Explore the reasoning
Withering did not run three regulatory phases, nor a double-blind placebo trial. Cardiac glycosides have a narrow safety margin, so even a completed modern programme would still require careful dosing and monitoring rather than a marketing slogan.
Recall this lesson
Lesson recall questions
Question 1 of 5: What is a placebo in a drug trial?
How drug testing developed
Practice question
Retrieval and explanation · suggested answer
What is a placebo in a drug trial?
Lesson: 4A 7: Developing New Drugs
Try this from memory first.
Put your biology to work
Explore where these ideas appear in the world. Enrichment, not extra required recall.
Reading the 1785 book as a source
4A · Developing New DrugsWellcome Collection holds Withering’s 1785 Account of the Foxglove, now in the public domain. Primary sources let you see the case notes and cautions rather than a simplified…Specification 4.13Read & use the scienceClose article
Why this matters
Wellcome Collection holds Withering’s 1785 Account of the Foxglove, now in the public domain. Primary sources let you see the case notes and cautions rather than a simplified textbook story. Use them as history of evidence, not as a modern dosing manual. Withering compared observations and adjusted doses, but his historical cases were not a modern randomised controlled trial. Current protocols begin with laboratory evidence and move through phased human testing, with placebos and blinding used where appropriate. A primary historical source helps students see why methods evolved. It is not evidence that a historical recipe should be followed today. The exam asks for the methodological development: identify which possible bias a design feature addresses and what each phase is intended to test.
Back to the specification
Pearson Edexcel IAL Biology · Issue 2, February 2021 · Unit 2, pp. 21–24. The application extends beyond required recall.
- 4.13 understand the development of drug testing from historic to contemporary protocols, including William Withering’s digitalis soup, double blind trials, placebo and three-phased testing
Use the science
What extra information in a primary case series still would not match a Phase III result?
Explore a possible response
Even detailed notes lack random allocation, blinding and a pre-specified comparison group large enough to separate the drug effect from confounding.
Explore the source
- Wellcome Collection: An Account of the Foxglove (Withering, 1785)Wellcome Collection
What a registered trial record tells you
4A · Developing New DrugsClinicalTrials.gov records study design features such as intervention, comparator, phase and planned outcome. A trial coordinator can use those fields to check whether a claim matches what was…Specification 4.13Read & use the scienceClose article
Why this matters
ClinicalTrials.gov records study design features such as intervention, comparator, phase and planned outcome. A trial coordinator can use those fields to check whether a claim matches what was actually tested. Phase I commonly focuses on safety; later phases collect stronger evidence about benefit in relevant groups. A placebo and blinding can reduce particular biases where ethically and practically appropriate. Registration is transparency, not proof that a treatment works. This modern tool contrasts with Withering’s historical case observations and helps students explain why drug testing developed over time. For exam answers, identify the control and the question it helps answer.
Back to the specification
Pearson Edexcel IAL Biology · Issue 2, February 2021 · Unit 2, pp. 21–24. The application extends beyond required recall.
- 4.13 understand the development of drug testing from historic to contemporary protocols, including William Withering’s digitalis soup, double blind trials, placebo and three-phased testing
Use the science
A trial registry lists an experimental drug and a placebo arm. Does that mean the drug has passed Phase III?
Explore a possible response
No. The record describes a design. The phase and completed results must be checked separately; planned comparison is not demonstrated effectiveness.
Explore the source
- ClinicalTrials.gov study terminologyUS National Library of Medicine